Infarct size was assessed quantitatively in 33 patients with acute myocardial infarction with a new technic based on analysis of serial serum creatine phosphokinase (CPK) changes to determine its relationship to prognosis. We have recently measured infarct size in the conscious dog with this method which takes into account CPK distribution space, fractional disappearance rate, proportion degraded in myocardium, and proportion released into the circulation, and we have validated the method by measurement of myocardial CPK depletion in the same animals. In the present study, CPK activity (determined spectrophotometrically) and isoenzyme profiles (assayed electrophoretically) were measured in patient serum samples obtained every 2 hours. Infarct size was estimated by mathematical analysis of serial CPK changes utilizing the method previously developed in the conscious dog model. CPK isoenzyme profiles demonstrated prominent anodal bands, absent from normal serum, indicating that enzyme elevations reflected CPK released from heart rather than skeletal muscle. In 19 class I-II survivors (New York Heart Association) estimated infarct size was 31 + 4 CPK-gram-equivalents (CPK-g-Eq). It was significantly larger (P < 0.01), 103 +-14, in nine patients who died and in four class III or IV survivors (91 8). Estimation of cumulative infarct size differentiated patients with electrocardiographic changes and clinical sequelae from complications such as pericarditis from those patients with extension of infarction. Thus, infarct size can be assessed quantitatively in patients with acute myocardial infarction and provide a useful diagnostic and prognostic index based on the extent of myocardial damage.
INFARCT SIZE IN MAN size and elucidation of the relationship between infarct size and prognosis in individual patients are necessary for assessment of efficacy of metabolic, pharmacologic, and surgical interventions in reducing infarct size and for appropriate selection of patients suitable for therapy associated with significant risk.
We have recently developed a method to measure infarct size noninvasively in the conscious dog on the basis of analysis of serial changes in serum creatine phosphokinase (CPK) activity. 4 Infarct size was directly related to myocardial CPK depletion.5' 6 Furthermore, CPK released into serum was a constant fraction of myocardial CPK depletion.4 CPK released could be calculated directly from serial serum enzyme values because the instantaneous disappearance rate of serum CPK was monoexponential with a constant fractional disappearance rate. In 22 conscious dogs, infarct size measured by this approach correlated closely with infarct size measured directly by analysis of myocardium in the same animals (r = 0.96, N = 22) . 4 Furthermore, alteration of infarct size produced by pharmacologic and physiologic interventions was reflected by corresponding changes in infarct size calculated indirectly from serum CPK changes and infarct size measured directly by analysis of myocardium.
In the present study estimation of infarct size by analysis of serial serum CPK changes was performed in patients with coronary artery disease. Infarct size was assessed by this technic in 33 patients admitted to the Myocardial Infarction Research Unit and related to clinical course and prognosis. Constants necessary for application of the mathematical analysis required to assess infarct size from serum CPK changes in man were obtained by determinations of CPK activity in human myocardium removed out of necessity during cardiac surgical procedures.
A new method of analysis of CPK isoenzyme profiles in serum and tissue extracts was utilized to ascertain the myocardial origin of CPK contributing to total serum CPK values Circulation, Volume XLVI, October 1972 employed in the mathematical analyses of infarct size.
Methods

Patients Studied
Consecutive patients with acute myocardial infarction studied in the Myocardial Infarction Research Unit within 24 hours after the onset of symptoms were included in this investigation, except for those with marked hypotension (systolic pressure less than 85 or diastolic pressure less than 60 mm Hg) at the onset of the CPK sampling period, or those whose serum CPK was already maximum at the time of admission. The diagnosis of myocardial infarction was based on the presence of at least two of the following three criteria: (1) characteristic chest pain of greater than 1-hour duration; (2) transmural electrocardiographic changes including evolution of q waves; and (3) serial elevations of serum glutamic oxaloacetic transaminase (SGOT), lactic dehydrogenase (LDH), and CPK conforming to the pattern typically seen in patients with myocardial infarction. The diagnosis was corroborated by the presence of an abnormal LDH1/LDH, ratio. Thus, in all patients this ratio exceeded 1 In the dog, only 30% of the enzyme activity lost from myocardium is released into the circulation; the remainder undergoes local degradation.4 In order to obtain the corresponding value for this fraction in man, analysis of myocardium obtained within minuutes after death would be required in a patient who died at a specified interval after the onset of his first episode of myocardial necrosis. Since such conditions are difficult to meet we have used the same fraction as that obtained in the dog (30%) in the present analysis. The fractional disappearance rate, kd, for CPK in man was estimated from the means of the terminal fractional disappearance rates observed in 24 patients with a single, discrete peak of CPK elevation, and was found to be 0.001 ± 0.0001 (mean + SE). The terminal portions of these curves were used on the assumption that additional myocardial CPK release into the circulation had ceased when CPK disappearance became monoexponential. The value used for Circulation, Volume Calculations of infarct size depend on the premise that CPK released into the circulation is derived from myocardium rather than other tissues such as skeletal muscle. Isoenzyme profiles of heart and skeletal muscle are shown in figure 1. As can be seen, heart muscle exhibits a prominent anodal band (MB) averaging 46% of total myocardial CPK (N =6 fresh samples from different hearts). On the other hand, skeletal muscle samples studied failed consistently to exhibit MB (N = 8 muscles). Furthermore, in six patients with shock not associated with myocardial infarction MB in serum averaged only 1% of total CPK activity (range 0-3) even when total activity was elevated 10-to 30-fold. However, in patients with myocardial infarction MB represented at least 10% of total serum CPK and at least 16 mIU/ml when samples were obtained 24 hours after the onset of chest pain (range 10-34%, mean 21%, N = 13). In samples obtained earlier, the percent MB and absolute MB activity were frequently even higher. The fractional disappearance rate of MB was 0.2 ± 0.01%/min (mean + SE, N = 5). A representative example of the disappearance of MB CPK compared with total CPK in the same patient is shown in table I. MB consistently disappeared much more promptly from serum than total CPK after myocardial infarction. In all patients studied markedly elevated total serum CPK activity was associated with the maximum percent MB seen in the same patient, and late elevations of total CPK were associated with late elevations of MB CPK. Accordingly, it is unlikely that spurious calculation of infarct size resulted from sigificant contributions of skeletal muscle CPK to total serum CPK activity. Thus, it appears that even in patients with severe hypotension, the method described is useful in determining infarct size when CPK isoenzyme determinations are performed on the same samples to exclude from the calculations total CPK elevations reflecting primarily contributions fiom skeletal muscle.
Infarct Size and Prognosis
Infarct size in CPK-g-Eq is closely related to mortality and to residual functional impairment in survivors. In the 33 patients studied there were nine deaths, eight of which resulted from power failure. The relationship between infarct size and mortality is illustrated in figure 3 . Eight of 12 patients with infarct size exceeding 65 CPK-g-Eq died. On the other hand, only one of 21 patients with infarct size less than 65 CPK-g-Eq died (P<0.001), and that death was sudden and unrelated to power failure. Infarct size in patients who died averaged 103 + 14 CPK-gEq (mean + SE) compared to 41 ± 6 CPK-gEq in survivors (P < 0.001).
In addition to mortality, infarct size was closely related to clinical class of survivors, as shown in figure 4 . In patients who died with power failure, infarct size averaged 109 ± 10 CPK-g-Eq. In patients who survived but manifested marked functional impairment (class III or IV) infarct size averaged 91 + 8 CPK-g-Eq. In the one patient who died without power failure, infarct size was only 50 CPK-g-Eq. In patients who survived without marked functional impairment (clinical class I or II) infarct size was 31 + 4 CPK-g-Eq. Infarct size in class III or IV survivors was significantly greater (91 ± 8) than in class I and II survivors (31 + 4) (P < 0.001). All patients with > 65 CPK-g-Eq infarcts were initially class I or II.
Infarct Size and Electrocardiographic Localization of Infarction
As shown in table 2, anterior transmural infarctions were considerably larger than inferior transmural infarctions in patients studied. Furthermore, subendocardial infarctio s were consistently smaller than transmural infarctions. The average infarct size in 14 patients with anterior infarction was 82 CPKg-Eq compared to 50 CPK-g-Eq in 14 patients with interior infarction and 14 CPK-g-Eq in five patients with subendocardial infarction. These findings are compatible with the prevailing view that subendocardial infarction generally involves a relativelv small mass of myocardium.
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